The Evolution from Fixed to Single-Use Systems - An overview of applications for disposable components and important property considerations. This article is part of a special issue on Single-Use Tech

ADVERTISEMENT

The Evolution from Fixed to Single-Use Systems
An overview of applications for disposable components and important property considerations. This article is part of a special issue on Single-Use Technologies.


BioPharm International Supplements
pp. s15-s20

CONCLUSION

Stainless steel continues to lead the way for mass-production drugs and fixed-system approaches. Disposables equipment has moved into the biotechnology–pharmaceutical mainstream. Only 3% of biopharmaceutical manufacturers use no disposables today, according to the Third Annual Report on Biopharmaceutical Manufacturing Capacity and Production, issued in June 2005 by BioPlan. Additionally, the Biopharm Miram Murge Study estimated capitol costs reduction of 40% by single use systems. This trend is expected to continue as the industry evolves into a more pragmatic approach to regionalized and smaller-dose drugs. The need for lighter and more efficient components and systems will become increasingly important as quick changeover and low costs move to the forefront. The PVDF fluoropolymer alternative has continued to gain acceptance as a single fluid contact surface as it offers biopharm engineers the advantage of reduced risk and a universal polymer-system approach.

Gary M. Dennis is market manager for highpurity fluropolymer resins, Charles Weidner is a business development manager, and Saeid Zerafati is a senior research engineer, all at Arkeme Inc., 900 First Avenue, King of Prussia, PA 19406. tel., 610.205.7535

REFERENCES

1. A. S. Brown, Chem. Process. (February, 2006).

2. D. R. Keer, Ultrapure Water (July/August 1993) 40–44.

3. R. Greene, Chem. Eng. Progress (July 2002) 15–17.

4. L. Shnayder, Pharm. Eng. (November/December 2001) 66-72.

5. W. J. Hartzel, Innov. Pharm. Technol. (22) 2008.

6. T. Sixsmith and B. Paul, Chem. Process. (September 1995) 86-89.

7. H. Gruen, M. Burkhart, and G. O'Brien, Ultrapure Water (October 2001) pp. 31-38.


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

First Biosimilar Application Kicks Off Legal Battle
October 31, 2014
FDA Approves Pfizer's Trumenba for the Prevention of Meningitis B
October 30, 2014
EMA: Extrapolation Across Indications for Biosimilars a Possibility
October 30, 2014
Bristol-Myers Squibb Announces Agreement to Acquire HER2-Targeted Cancer Treatment
October 29, 2014
Amgen, Sanofi, and Ono Pharmaceuticals Partner with Universities on Transmembrane Protein Research
October 28, 2014
Author Guidelines
Source: BioPharm International Supplements,
Click here